Summary for ARTG Entry:
APO-LEFLUNOMIDE leflunomide 20mg tablets bottle
ARTG entry for
Apotex Pty Ltd
PO Box 280,NORTH RYDE BC, NSW, 1670
ARTG Start Date
Drug Safety Evaluation Branch
Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods
Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered
or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.
1. APO-LEFLUNOMIDE leflunomide 20mg tablets bottle
Single Medicine Product
See Product Information and Consumer Medicine Information for this product
Apo-Leflunomide is indicated for the treatment of active rheumatoid arthritis. The combined use of Apo-Leflunomide with other disease modifying
antirheumatic drugs (DMARDs) has not been adequately studied (see Precautions).
Additional Product information
Store below 25
Neither child resistant
closure nor restricted
Pack Size/Poison information
(S4) Prescription Only Medicine
1. APO-LEFLUNOMIDE leflunomide 20mg tablets
Route of Administration
White, arc-triangular shaped tablet. Engraved "LE" over "20" on one side
and "APO" on the other side.
© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior
written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.
Page 1 of
Produced at 29.11.2017 at 03:46:04 AEDT
This is not an ARTG Certificate document.
The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.
Visit www.tga.gov.au for contact information